Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Imvexxy

Phase 3Small molecule

Imvexxy is one of 6 small molecule programs targeting Dyspareunia. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

5

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyspareuniaActive, not recruiting

DyspareuniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Dyspareunia

#DrugCompanyPhaseTrials

Estrace

Intrarosa

Alnylam Pharmaceuticals

Andriol

Osphena

DDuchesnay Inc.

Imvexxy

Xylocaine

MMEDRx USA, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dyspareunia1 trial

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

Completed· Teva logo

Teva·Phase 3·NCT05617820·1,050 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Imvexxy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Imvexxy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Imvexxy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Teva

Related News